Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Review

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Research Support, N.I.H., Extramural

Clinical Trial, Phase II

Clinical Trial, Phase I

Comparative Study

Observational Study

Network Meta-Analysis

Clinical Trial

Multicenter Study

Publication Year

From

Quick links

Individual year

2026

2024

2022

2021

2020

2018

2016

2015

2014

2013

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Epithelial Sodium Channel Blockers""[mesh_terms]

22 Results

Searching titles within these results

Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells.

Kristina Kusche-Vihrog, Frederic Jaisser, Thomas R Kleyman, Hans Oberleithner, Shaohu Sheng, Antoine Tarjus, David G Warnock

Nature reviews. Nephrology 2014;10(3):146-57

Free Full Text

Abstract

ENaC regulation by proteases and shear stress.

Thomas R Kleyman, Rebecca P Hughey, Marcelo D Carattino, Shujie Shi

Current molecular pharmacology 2013;6(1):28-34

Free Full Text

Abstract

Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.

Pradeep Kota

Current opinion in pharmacology 2022;64():102209

Full Text

Abstract

Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study (AMILOR).

Daniel Essigke, Elisabeth Vogel, Matthias Wörn, Bernhard N Bohnert, Andreas L Birkenfeld, Ferruh Artunc, Nils Heyne, Imma Fischer, Anja Schork

Acta physiologica (Oxford, England) 2024;240(8):e14183

Full Text

Abstract

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

Margaret W Leigh, Maimoona A Zariwala, Michael R Loebinger, Menno M van der Eerden, Karl H Donn, Massimo Pifferi, Henryk Mazurek, Kim G Nielsen, Adam J Shapiro, Felix C Ringshausen, Michael R Knowles, Thomas W Ferkol

The Lancet. Respiratory medicine 2024;12(1):21-33

Full Text

Abstract

Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis.

Scott H Donaldson, Ashley G Henderson, William D Bennett

Annals of the American Thoracic Society 2018;13 Suppl 2(Suppl 2):S186-90

Free Full Text

Abstract

ENaC modulators and renal disease.

Diego Alvarez de la Rosa, Juan F Navarro-González, Teresa Giraldez

Current molecular pharmacology 2013;6(1):35-43

Full Text

Abstract

Pharmacological treatment of aldosterone excess.

Jaap Deinum, Niels P Riksen, Jacques W M Lenders

Pharmacology & therapeutics 2016;154():120-33

Full Text

Abstract

Does a single oral administration of amiloride affect spontaneous arterial baroreflex sensitivity and blood pressure variability in healthy young adults?

Michael D Herr, Paul C Dalton, Cheryl Blaha, Takuto Hamaoka, J Carter Luck, Jon Stavres, Lauro C Vianna, Piotr K Janicki, Igor A Fernandes, Jeann L Sabino-Carvalho, Victor Ruiz-Velasco, Zyad J Carr, Jian Cui, Qudus A Ojikutu, Aimee E Cauffman

Journal of neurophysiology 2024;132(3):922-928

Free Full Text

Abstract

Outcomes of drug-based and surgical treatments for primary aldosteronism.

Olivier Steichen, Aurelien Lorthioir, Franck Zinzindohoue, Pierre-François Plouin, Laurence Amar

Advances in chronic kidney disease 2016;22(3):196-203

Free Full Text

Abstract

Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411.

John H Ansede, A Bruce Montgomery, M Ross Johnson, Vicki Shigekane White, William D Flitter, Sandra A Lewis, Terry Newcomb, Peter Hodsman, Karl H Donn, Thomas G O'Riordan, Richard C Boucher, David G Warnock

Journal of aerosol medicine and pulmonary drug delivery 2015;27(3):200-8

Full Text

Abstract

First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis.

Elizabeth Tullis, Robert Tarran, Timothy Crowder, Christie Hudson, Katherine Griffin, Leena Rizvi, Paulina Farias, Peter Couroux

Pulmonary pharmacology & therapeutics 2020;58():101819

Full Text

Abstract

Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.

Juan Tamargo, Julián Segura, Luis M Ruilope

Expert opinion on pharmacotherapy 2014;15(5):605-21

Full Text

Abstract

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Steven M Rowe, Nicole Mayer-Hamblett, Marcus A Mall

American journal of respiratory and critical care medicine 2020;201(10):1193-1208

Free Full Text

Abstract

Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials.

Yi-Liang Tsou, Yu-Hung Wang, Yi-Siou Lin, Chia-Liang Chen

Journal of clinical hypertension (Greenwich, Conn.) 2026;28(9):e70365

Full Text

Abstract

Results: 1 – 15 / 22

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Epithelial Sodium Channel Blockers""[mesh_terms]

Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells.

ENaC regulation by proteases and shear stress.

Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.

Amiloride versus furosemide for the treatment of edema in patients with nephrotic syndrome: A pilot study (AMILOR).

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis.

ENaC modulators and renal disease.

Pharmacological treatment of aldosterone excess.

Does a single oral administration of amiloride affect spontaneous arterial baroreflex sensitivity and blood pressure variability in healthy young adults?

Outcomes of drug-based and surgical treatments for primary aldosteronism.

Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411.

First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis.

Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials.

Results for
""Epithelial Sodium Channel Blockers""[mesh_terms]